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I Introduction and objective of this report
This report provides an update on infectious diseases 
related to drug use in Europe for the period up to June 
2017. It provides an overview of the most recent data both 
on infectious diseases among people who inject drugs in 
Europe, collected through the EMCDDA drug-related 
infectious diseases (DRID) indicator (1), and on the 
(1) More information of the key indicator is available from www.emcdda.
europa.eu/activities/drid.
responses in the area. It includes highlights and new 
findings discussed during the DRID indicator’s annual 
expert meeting, held in Lisbon on 14-16 June 2017. This 
event offered a platform for discussion among experts 
from the 28 EU Member States, Norway and Turkey. EU 
agency partners and international organisations were also 
represented (2). The 2017 meeting included a full joint day 
with the ECDC hepatitis expert network (EMCDDA, 2017a).
(2) Information on the meeting, including the agenda, presentations and 
supporting documents, is available at the DRID meeting webpage.
Injecting: In Europe, overall, heroin is the most commonly 
injected illicit drug. In some countries, however, injection of 
stimulants is common among those who inject drugs. 
Recent national estimates (from 2009 onwards) of the 
prevalence of injecting drug use are available for only 16 of 
the 30 countries reporting to the EMCDDA. The estimates 
range from less than 1 to more than 9 per 1 000 population 
aged 15-64. A downward trend can be observed in the 
proportion of people who inject drugs among those 
entering specialised drug treatment for heroin-related 
problems for the first time in their life (from 43 % of heroin 
users in 2006 to 29 % of heroin users in 2015), but levels of 
injecting remain high (46 %) among amphetamines users 
entering drug treatment for the first time in 2015 — 
although the number of people injecting amphetamines is 
small and they are concentrated in a few countries.
Hepatitis C virus (HCV): Hepatitis C is the most prevalent 
blood-borne virus infection among people who inject drugs, 
with the prevalence of HCV antibodies (i.e. marker of having 
been infected by the virus) often in excess of 50 %. The 
majority of those infected will develop chronic infection; 
however, there are now very effective treatments. These 
treatments, when provided alongside harm reduction 
measures, are important for eliminating hepatitis C as a 
public health threat among people who inject drugs. There 
are many challenges to delivering the WHO Global Health 
Sector Strategy for the elimination of viral hepatitis, and 
monitoring is important to assess progresses towards the 
targets that have been set for hepatitis C. For people who 
inject drugs or have done so in the past, these challenges 
include the uptake of diagnostic testing, and unclear referral 
and care pathways between testing and treatment.
Human immunodeficiency virus (HIV): Europe is seeing a 
continuing decline in the reported number of new HIV 
diagnoses attributed to injecting drug use. The 1 233 
diagnoses with this risk factor reported in 2015 were the 
lowest for a decade. Nevertheless, the number of new HIV 
diagnoses and the prevalence of HIV among people who 
inject drugs remain high in a number of countries, 
particularly Estonia, Latvia and Lithuania. Local HIV 
outbreaks among marginalised groups of people who inject 
drugs have recently occurred in Dublin (Ireland), Glasgow 
(United Kingdom) and Luxembourg.
Outbreaks of other infections: A range of other infections 
continue to cause outbreaks among people who use drugs. 
Examples include the recent outbreaks of invasive group A 
streptococcal infections in the United Kingdom and of 
hepatitis A in the Czech Republic. There is also an ongoing 
large outbreak of hepatitis A among men who have sex with 
men in Europe, and drug use in a sexual context may have 
been a factor in the development of this outbreak in some 
countries.
Prisons and hepatitis C: Prisons pose particular challenges 
to reducing the burden of infectious disease, and those 
who have been imprisoned report higher levels of lifetime 
drug use than the general population. There is an elevated 
risk of transmission of infections associated with 
imprisonment. Effective interventions for prevention and 
control of viral hepatitis that are implemented in the 
community are not always available in prison; where they 
are, their introduction has typically been later than in the 
community. Opportunities exist for scaling up hepatitis C 
prevention, diagnosis and treatment in prisons.
Drug consumption rooms: Drug consumption rooms are 
professionally supervised healthcare facilities where drugs 
can be used in a safe, hygienic environment. In Europe, as 
of June 2017, there were 90 official drug consumption 
rooms, of which 76 were in six EU countries (31 in the 
Netherlands, 24 in Germany, 13 in Spain, five in Denmark, 
two in France and one in Luxembourg), two in Norway and 
12 in Switzerland. A number of countries are currently 
looking to expand their provision, and several others are 
currently considering the establishment of facilities.
At a glance: a summary of key points
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The DRID annual network meetings primarily aim to share 
and discuss the analysis of national and European data. 
They also explore new developments, and their 
implications for actions and policy development. It should 
be noted that, as this publication is, in part, based on the 
presentations to the meeting and emerging issues, some 
of the information presented here is necessarily 
preliminary.
In addition, this report uses information provided by 
countries in their ‘national DRID updates’ in the spring of 
2017. It also draws on analysis of the information provided 
to the EMCDDA by the national focal points and their 
experts in the 2016 annual reporting exercise, the main 
findings of which are presented in the European Drug 
Report 2017 and also available through the Statistical 
Bulletin (EMCDDA, 2017b; EMCDDA, 2017c).
The multi-indicator data set used in the analysis covers 
and integrates aspects of the epidemiology (prevalence of 
injection, prevalence of infections among people who 
inject drugs, notifications of newly diagnosed infections, 
risky behaviours, morbidity and outbreaks) and responses 
(prevention, testing for infections, treatments for addiction 
and infections, and harm reduction).
I  Overview of drug-related infections and risk
This section presents an overview of injecting drug use in 
Europe, and of the epidemiology and responses to 
hepatitis C among people who inject drugs. It also provides 
updates on the epidemiology and responses to other 
infections, including hepatitis B and HIV, and on recent 
outbreaks among people who inject drugs in Europe.
I  Introduction: the extent and nature of injecting drug use in Europe
People who inject drugs are one of the main population 
groups affected by blood-borne viruses, in particular the 
hepatitis C and B viruses (HCV and HBV) and human 
immunodeficiency virus (HIV), as these three viruses can 
be transmitted through the sharing of syringes, needles 
and other drug injecting equipment. Recent national 
estimates (from 2009 onwards) of the prevalence of 
injecting drug use are available for 16 countries. These 
range from less than 1 to more than 9 cases per 1 000 
population aged 15-64 (Figure 1; Appendix 1). The highest 
rates are reported from Latvia (9 cases per 1 000 
population) and the Czech Republic, Estonia and 
Luxembourg (each with around 6 cases per 1 000 
population). However, caution is needed in interpreting 
these data, as the most recent estimate for Latvia is from 
2012 and the estimates for Estonia and Luxembourg are 
from 2009.
Historically, in Europe, the most common route of 
administration of heroin has been by injection, and, among 
people who inject drugs, heroin users have been the 
majority. Information on people entering drug treatment for 
the first time in their life, however, shows a downward 
trend in the proportion of those using heroin who report 
injection as their usual route of drug administration. Over 
the past 10 years this proportion has fallen from 43 % in 
2006 to 29 % in 2015. The second-largest group of people 
who inject drugs, among those entering drug treatment for 
the first time, are those whose primary drug is an 
amphetamine (commonly amphetamine and 
methamphetamine). Overall, amphetamines users 
represented 8.4 % of first-time clients in 2015 in the 
European Union and only a few countries reported 
significant numbers injecting amphetamine or 
methamphetamine in their treatment data. However, these 
data are heavily influenced by the situation in the Czech 
Republic, which accounted for almost all the first-time 
clients reporting the injecting of methamphetamine (94 % 
of the European total).
FIGURE 1
Estimates of the prevalence of injecting drug use, 2009-
15 (most recent data)
>5.0 2.51–5.0 0–2.5 No dataCases per 1 000 
population aged 15–64  
NB: Case definition: injecting use of any psychoactive substance not accord-
ing to medical prescription in the last 12 months (www.emcdda.europa.eu/
activities/hrdu). See also Appendix 1. 
Source: EMCDDA, 2017c.
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The emergence of injecting use of new psychoactive 
substances, reported in a number of countries, has caused 
particular concern in recent years (EMCDDA and 
EUROPOL, 2017). The injection of synthetic cathinones, 
which are short-acting stimulants, has been associated 
with increased infection risk and harms, for example, 
outbreaks of HIV (EMCDDA, 2016a; EMCDDA, 2017b). 
Timely detection of the use of new and emerging drugs, as 
well as ongoing monitoring of risky drug use practices 
(such as injecting and sharing of injecting equipment), and 
detecting changes in these, is important to reducing and 
preventing harm.
I HCV incidence, prevalence and trends
Studies among people who inject drugs conducted in 
2014-15 found that the prevalence of antibodies to HCV 
(anti-HCV) — a marker of present or past infection — was 
between 16 % and 84 %, with most of the studies with 
national or subnational data showing levels over 50 % 
(Figure 2). Recent data (from 2014 or later) on the extent 
of HCV infection among people who inject drugs are 
available from 24 countries, and come from a range of 
study types. Sero-prevalence surveys are reported by 13 
countries, seven of which have repeated surveys (Greece, 
Hungary, Latvia, Slovakia, the United Kingdom, Norway and 
Turkey). For 11 countries, the only recent data available on 
the extent of viral hepatitis is from diagnostic testing; 
however, 10 of these countries have time trends. This 
diversity in data sources means that comparisons should 
be made with caution.
The high prevalence of HCV among people who inject 
drugs in Europe, and the fact that many of them became 
infected a long time ago, has a severe impact on the overall 
health of these populations in Europe. Chronic HCV 
infection, often worsened by heavy alcohol use, accounts 
for an increasing number of cases of liver disease, 
including cirrhosis and liver cancer, and an increasing 
number of deaths (Stanaway et al., 2016), among an 
ageing population of people who use or have used drugs 
by injection.
The incidence of new HCV infections is difficult to 
estimate directly, as this requires studies that follow up 
those at risk over time. Incidence can also be estimated 
through statistical methods from survey data (Léon et al., 
2016) and by using biological markers (Page-Shafer et al., 
2008; Patel et al., 2016). Alternatively, the extent of recent 
transmission can be assessed by looking at the prevalence 
of HCV antibodies among those who have recently started 
injecting and among younger people who inject drugs 
(aged 25 years or younger). Infections of individuals in 
FIGURE 2
Prevalence of HCV antibodies among people who inject drugs: studies with national and subnational coverage, 2014-15
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these groups are likely to have occurred recently. There 
were 25 countries with data available for younger people 
who inject drugs (2014-15). In many of them, the 
prevalence in this group is over 20 % (Figure 3; 
Appendix 2), indicating ongoing transmission.
Most HCV prevalence estimates among younger people 
who inject drugs are between 20 % and 60 %, whereas 
most prevalence estimates among older people who inject 
drugs (those aged 35 years and over) are between 40 % 
and 80 %, highlighting the accumulation of risk over the 
years and a high burden of infection among the older 
groups (Figure 3).
The current monitoring of HCV focuses on the collection of 
data on HCV antibodies. However, monitoring HCV 
ribonucleic acid (RNA), a marker of current infection, is 
now becoming important — see the box on monitoring 
HCV infection (page 8).
The high level of HCV among those who have injected 
drugs is mirrored by data on new diagnoses reported to 
ECDC. In 2015, 34 651 cases of hepatitis C were reported 
from 28 EU/EEA Member States, a crude rate of 8.6 per 
100 000 population (ECDC, 2017a). Although information 
on the likely route of transmission was available for only 
approximately 14 % of the HCV diagnoses notified in the 
European Union during 2015, injecting drug use was the 
risk reported for 75 % of these newly notified diagnoses. 
The interpretation of HCV data across countries remains a 
problem, with ongoing differences in surveillance systems 
and difficulties in defining reported cases as acute or 
chronic. With HCV, a largely asymptomatic disease until 
the late stages, surveillance based on notification data is 
challenging, with data reflecting testing practices rather 
than the occurrence of disease.
FIGURE 3
Prevalence of hepatitis C infection among people who inject drugs, by age; studies with national and subnational 
coverage, 2014 to 2015
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NB: The heavy lines in the graphics highlight the differences in the distributions of the two age groups. Studies with sample size of at least 10 are not available 
for all countries.
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The development of highly effective direct-acting 
antiviral drugs for HCV infection has resulted in more 
effective and easily deliverable treatment. As a result, 
more people are now being successfully treated. This 
has implications for monitoring HCV infection among 
people who use drugs. The biological marker of infection 
that is most commonly used currently in the monitoring 
of HCV prevalence is antibodies to HCV. As only around 
a fifth to a quarter of people naturally clear HCV infection, 
this marker has been a useful proxy for the extent of chronic 
infection. However, those who are successfully treated 
remain positive for HCV antibodies even though they are no 
longer infected. Thus, as the number of people successfully 
treated increases, this marker will have more limited utility 
for measuring the extent of current infection. There is a 
good marker of current infection, which is the presence of 
HCV RNA; however, testing for this marker is currently less 
common because it often costs more.
An example of survey development to improve monitoring 
of HCV prevalence among people who inject drugs was 
presented at the DRID meeting. The national Unlinked 
Anonymous Monitoring (UAM) survey of people who inject 
drugs in the United Kingdom (excluding Scotland) has 
recently undergone a number of developments, in part to 
reflect the impact of new direct-acting antiviral drugs on 
HCV (Desai, M., DRID meeting, 2017). The recruitment 
method used in this long-standing system has remained 
the same, but two changes have been made. Firstly, the 
survey questionnaire has been revised to better capture 
data related to access to HCV treatment and care. 
Secondly, and more significantly, a cost-neutral 
restructuring of the testing of the samples collected, 
involving moving to an automated approach, has allowed 
the introduction of the routine HCV RNA testing of all 
samples collected in the survey. This will allow not only the 
ongoing monitoring of the extent of the current HCV 
infection, but also the monitoring of HCV incident infections 
by detecting HCV RNA in those without antibodies, which 
indicates recent infection.
The reporting to EMCDDA of information on HCV RNA 
prevalence among people who inject drugs is currently an 
optional data item. Following discussion at the meeting, it 
was proposed to make reporting this information a core 
data item, to encourage countries to collect this data.
Monitoring hepatitis C infection among people who use drugs in the era of 
direct-acting antivirals
I HCV prevention and treatment
Those currently injecting drugs are thus the main target 
group for prevention activities, and they and those who 
have injected in the past are important groups for the 
provision of treatment for HCV.
The HCV landscape has changed with the development of 
a range of very effective direct-acting antiviral drugs 
(DAAs), which became available in Europe in 2014. 
Treatment with these drugs can cure HCV infection in 
almost all those affected (EASL, 2016). However, those 
who have been cured may remain at risk of liver problems, 
such as fibrosis, and will still require follow-up. Although 
many DAAs are available, overall provision is currently low 
and the scale-up of provision for people who have injected 
or inject drugs is often slow.
Treating HCV among people who inject drugs on sufficient 
scale is very likely to have a positive contribution to 
prevention activities (EMCDDA, 2016b). ‘Treatment as 
prevention’, as this approach is called, results from the 
additive effect of treating HCV among those actively 
injecting alongside two established interventions that are 
known to reduce risk. These interventions are needle and 
syringe programmes, which aim to ensure that clean, 
sterile injection equipment is always used, and opioid 
substitution treatment, prescribing drugs that are taken 
orally to reduce the frequency of injection. Adequate 
coverage of these two interventions is important for their 
effectiveness; however, the available data suggest that the 
provision of these interventions still remains low in relation 
to needs in some European countries (Platt et al., 2017).
Needle and syringe programmes are available in all 
European countries (Figure 4), but the geographical 
spread is poor in a number of countries (Figure 4). 
National-level data on the estimated coverage of needle 
and syringe programmes (calculated as the number of 
syringes distributed from specialised and publicly 
subsidised programmes annually per person who injects 
drugs) is available for only 15 countries, with only three of 
these (Estonia, Finland and Norway) estimating coverage 
above 200 syringes per person who injects drugs 
(Figure 5).
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FIGURE 4
Availability of specialist needle and syringe programmes in the European Union, Norway and Turkey
Percentage of territorial units with 1 or more outlets
<20 20–39 40–59 60–79 >80 No data
NB: Percentage of NUTS-III standardised European territorial units with one or more outlets (NUTS-II for Spain, Italy, Netherlands, Austria). Availability may not 
be throughout each NUTS, or indicate if coverage within this territory is sufficient.  
Source: (EMCDDA, 2017c).
FIGURE 5
Coverage of specialised syringe programmes: number of syringes provided per person who injects drugs (estimate)
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Oral opioid substitution treatment is effective in reducing 
the harm from opioid addiction (EMCDDA, n.d.). The 
coverage of opioid substitution treatment, calculated as 
the percentage of estimated high-risk opioid users 
receiving the treatment, is estimated at over 50 % in 10 of 
the 17 countries for which estimates of the population of 
high risk opioid users are available, and less than 30 % in 
four countries (Figure 6). 
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These data indicate a need to improve the coverage of one 
or both of these interventions in many countries. Data on 
the number of syringes given out or on the number of 
people in opioid substitution treatment are available for 
most countries, but coverage estimates cannot be 
generated for lack of estimates of the population size to 
use as a denominator (Appendix 1).
Available data on the extent of access to, and uptake of, 
treatment for HCV among those who have acquired their 
infection through injecting drug use is currently limited in 
Europe. The multistage process from access to diagnostic 
testing to cure is often referred to as the HCV cascade of 
care. The EMCCDA, together with the EU Member States, 
Norway and Turkey, is currently trying to improve data 
collection for key components of the HCV cascade of care 
for people who inject drugs. Core data collected by the 
EMCDDA related to HCV prevalence and prevention are 
summarised in Appendix 2, and a discussion is ongoing 
among national experts on how this dataset could be 
expanded to include markers related to diagnosis, care and 
treatment. In this context, it should be noted that data on 
prevention and the continuum of care are important for 
monitoring progress towards the targets for hepatitis C in 
the WHO Global Health Sector Strategy for viral hepatitis 
(WHO, 2016a) and the regional targets for Europe (Duffell 
et al., 2017; see below).
Hepatitis C strategies, action plans and indicators
The first ever Global Health Sector Strategy for Viral 
Hepatitis (2016-21), adopted in May 2016, aims to 
eliminate viral hepatitis — including hepatitis B and C — as 
a major public health threat by 2030 (WHO, 2016a). As 
part of the implementation of this strategy, a European 
Action Plan was approved in September 2016. This plan is 
tailored to the specific needs of the WHO European Region 
(WHO European Office, 2016). These two documents set 
targets for actions to deliver the ‘elimination’ of hepatitis B 
and C. The EMCDDA and ECDC are supporting the 
strategy by assisting countries in the monitoring of its 
implementation and the achievement of the European 
regional targets.
Equitable access to hepatitis treatment is one of the 
progress indicators in the global hepatitis strategy set out 
by the WHO. In the European Region, the Action Plan for 
the health sector response to viral hepatitis proposes as 
one of its milestones for the development of evidence-
FIGURE 6
Coverage of opioid substitution treatment (percentage of estimated high-risk opioid users receiving the intervention)
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based policies in all countries by 2018, the existence of ‘a 
costed and funded national hepatitis plan with clear 
targets or a viral hepatitis response plan in a broader 
health strategy or action plan’. In order to support the 
documentation of progress made towards this milestone, 
and also to promote the exchange of good practice, the 
EMCDDA has compiled a list of national hepatitis policy 
documents (national strategies, action plans and clinical 
guidelines) from all EU countries plus Norway and Turkey, 
which are being reviewed with regard to their relevance for 
inclusion of people who inject drugs.
First results of the analysis of these documents were 
presented at the meeting (Nielsen, S., DRID 2017), and 
showed that 13 European countries (Belgium, Denmark, 
Germany, Spain, Ireland, France, Italy, Netherlands, 
Slovenia, Finland, Sweden, United Kingdom, Norway) have 
viral hepatitis strategies. Several of these had been revised 
or newly developed since the direct-acting treatments for 
HCV became available in 2014. Five countries (Greece, 
Latvia, Luxembourg, Poland, Portugal) mentioned being in 
the process of preparing national hepatitis strategies with 
the involvement of multiple stakeholders. Among countries 
which currently do not have a strategy, several recently 
updated their national clinical treatment guidelines for 
HCV treatment.
The latest guidelines from the European Association for 
the Study of the Liver (EASL, 2016) and from the WHO 
(2016b) recommend prioritising the treatment of people 
who inject drugs and have HCV, in order to reduce 
transmission, but the preliminary analysis seems to 
indicate that few countries implement this.
The example of Portugal, where there is a national 
treatment register but no national strategy, shows, 
however, that other approaches, such as clear clinical 
guidelines in combination with strong political lobbying 
supported by pharmaceutical firms and civil society 
involvement, can help to increase treatment access among 
people who inject drugs.
I HBV prevalence and vaccination levels
Hepatitis B virus can be transmitted through injecting drug 
use; however, unlike for HCV, there is currently an effective 
and safe vaccine available (ECDC, 2017b). Although most 
countries now have universal HBV vaccination 
programmes, these have mostly been introduced in recent 
decades. As a result, some cohorts of people who inject 
drugs will not have been vaccinated. The provision of 
catch-up programmes for these groups is therefore 
necessary. A few countries have targeted programmes 
focusing on those at greatest risk, including people who 
inject drugs. The extent of vaccine uptake among those at 
risk through drug use is not always well known and is likely 
to vary from country to country.
Information about the extent of current HBV infection 
among people who inject drugs (2014-15) is available for 
16 EMCDDA countries. In most of them, the prevalence of 
HBsAg (a marker of chronic carriage of the virus) is under 
5 %, although prevalence is higher in national or 
subnational studies of people who inject drugs from 
Belgium, Greece, Spain, Lithuania, the Netherlands, 
Austria, Portugal and Romania (Figure 7).
I HIV notifications, prevalence and trends
The transmission of HIV through injecting drug use 
continues in Europe, especially in eastern countries, even 
though there are effective public health intervention 
measures to prevent this. In countries participating in the 
EMCDDA annual data collection exercise (European Union, 
Norway and Turkey), transmission of the virus through 
injecting drug use has declined overall. In 2015, there were 
only 1 254 cases of newly reported HIV diagnoses 
attributed to injecting drug use, compared with 
2 158 cases in 2012 (EMCDDA, 2017b; ECDC, 2015).
FIGURE 7
HBsAg prevalence among people who inject drugs: 
studies with national and subnational coverage, 2014-15
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Over the past decade, the number of newly diagnosed HIV 
cases attributed to injecting drug use in the European 
Union plus Norway and Turkey has fallen from 2 260 in 
2006 to 1 254 in 2015; with 1 233 diagnoses reported in 
the European Union during 2015 (EMCDDA, 2017b; ECDC 
and WHO, 2016). This overall declining trend was 
interrupted in 2011-12, when a significant increase in new 
infections occurred as a result of localised outbreaks in 
Athens and Bucharest. A number of EU countries have 
much higher than average proportions of HIV diagnoses 
attributed to injecting drug use, reaching one quarter or 
more of all the cases reported (where transmission route is 
known) in Lithuania (34 %, 44 cases), Latvia (32 %, 
88 cases), Luxembourg (27 %, 14 cases), and Estonia 
(25 %, 55 cases) (EMCDDA, 2017b) (see also the section 
‘Update on HIV outbreaks’, below).
Recent estimates (2014-15) of HIV prevalence among 
people who inject drugs are available for all (EU Member 
States (excluding Denmark, Ireland, France and Sweden) 
and for Norway and Turkey. While the prevalence of HIV 
infection among people who inject drugs is currently below 
5 % in most of the countries with data, prevalence levels of 
5 % to 10 % are reported from national studies carried out 
in Greece, Luxembourg and Austria, and from national and 
subnational studies in Belgium and Germany. Higher HIV 
prevalences, of more than 10 %, have been reported from 
studies in Estonia, Greece, Spain, Italy, Latvia, Lithuania, 
Portugal and Romania.
I Outbreaks
Update on HIV outbreaks
Localised outbreaks of HIV among people who inject drugs 
have been reported in some European countries. A very 
large outbreak of HIV associated with injecting drug use in 
Athens (Greece) peaked in 2012 but has now been brought 
under control. Similarly, following the HIV outbreak in 
Bucharest (Romania) that occurred in 2011-12, the number 
of new diagnoses associated with injecting drug use in this 
country is continuing to decline. There have also been 
smaller outbreaks reported in Glasgow (United Kingdom) 
in 2016, Dublin (Ireland) and Luxembourg both in 2015. A 
number of factors have been associated with these 
outbreaks, including cocaine use (Glasgow, United 
Kingdom, and Luxembourg) and homelessness (Glasgow, 
United Kingdom, and Dublin, Ireland) (EMCDDA, 2016a).
An update on the HIV outbreak among people who inject 
drugs in Luxembourg was presented at the expert meeting 
(Devaux, C., DRID meeting, 2017). There had been a marked 
increase in numbers of new diagnoses of HIV associated 
with injecting drug use in 2014, and this was sustained 
through to 2016. The outbreaks involved two distinct HIV 
subtypes. One of these was found in a cluster of cases in 
Luxembourg city and the other was focused in cases 
reported in the south of the country. Risk analysis identified 
polydrug use as an important factor, related to a recent 
increase in cocaine injecting. A range of interventions, 
including improved outreach for those not in treatment, are 
being implemented as a response to this development.
Hepatitis outbreaks
Hepatitis C: Outbreaks of HCV among people who inject 
drugs are probably common, but not often detected, partly 
because any acute symptoms are usually mild and often 
go unnoticed. The response to an HCV outbreak in 
Northern Ireland (United Kingdom) that was detected 
through the routine diagnostic testing was presented at 
the expert meeting (Jessop, L., DRID meeting, 2017). 
Three cases of acute hepatitis C were diagnosed within 
one week in one town during the summer of 2016; this was 
very unusual. The cases were all in people who injected 
drugs and were homeless. In response, the homeless 
nursing team initiated outreach work to trace contacts and 
provide information and advice. Twelve contacts were 
initially identified: four tested positive for HCV and two 
were known to have chronic infections. A further outbreak 
case was also identified elsewhere at this time. Two 
further waves of contact tracing and testing have followed 
so far. At the time of the DRID meeting (June 2017), 
28 positive cases had been identified (eight were women 
and the mean age of the whole group was 29 years), nine 
of which were defined as acute, and genetic analysis 
indicates viruses with three distinct lineages. The acute 
group had mostly started injecting recently, mainly used 
heroin, often injected in groups, were commonly injected 
by others and shared injecting equipment, although not 
usually needles. Responses included individual and group 
advice; information posters and leaflets (Figure 8); the 
promotion of non-injecting routes of administration (advice 
on smoking heroin and foil provision); extending provision 
of injecting equipment and sharps packs to hostels; 
offering hepatitis B vaccination; and referrals for drug 
treatment assessment. In addition, the frequency of 
offering diagnostic testing was increased to every three 
months for those at ongoing risk, and the use of dried 
blood spot testing was expanded. Those who had, or 
developed, chronic infection were referred for hepatitis C 
treatment.
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Hepatitis A: Outbreaks of hepatitis A among those using 
drugs or associated with sexual activity continue to be 
reported, even though an effective vaccine is available. 
There is currently a large Europe-wide outbreak of 
hepatitis A among men who have sex with men, in which 
drug use has played a role in some countries a (see section 
‘Drug use and sexual risks among men who have sex with 
men’, below). Two outbreaks in the Czech Republic were 
reviewed at the expert meeting: both were among 
homeless people who use drugs (Janikova, B., DRID 
meeting, 2017).
In the Karlovy Vary Region in the west of the Czech 
Republic, there was an outbreak of viral hepatitis A 
infection from 2014 to July 2016. There were 339 cases 
reported, with 114 (34 %) in people using drugs who lived 
in precarious housing and mostly injected 
methamphetamine. In response, active case finding, 
targeted outreach prevention and health promotion 
activities were undertaken.
The second ongoing outbreak was in the South Moravian 
Region, in the south-east of the Czech Republic. It started 
towards the end of 2015 and at the time of the DRID 
meeting, in June 2017, 501 cases had been reported. The 
cases are mainly in people aged between 24 and 35 years, 
and either using drugs or without stable housing and 
employment. Vaccination of over-18s in the general 
population is recommended in the Czech Republic and is 
mandatory for specific at-risk groups, such as healthcare 
professionals (ECDC, 2016a). Targeted vaccination of 
contacts has been implemented in response to these 
outbreaks.
Bacterial infections and outbreaks
Drug injection is a risk factor for other infectious diseases, 
in particular bacterial infection. People who inject drugs 
are particularly vulnerable to skin and soft tissue infections 
at injection sites. They are also at risk of infections caused 
by spore-forming bacteria, such as tetanus and botulism. 
The spores that these bacteria produce are found in the 
environment and can contaminate drugs.
Clusters and sporadic cases of wound botulism among 
people who inject drugs have been reported by several EU 
countries and Norway over the last two decades (ECDC 
and EMCDDA, 2015). During 2016, cases of wound 
botulism among people who inject heroin were reported in 
Germany (ECDC, 2016b) and in the United Kingdom. More 
recently an outbreak of an uncommon type of group A 
streptococcal infection among homeless people, many of 
whom were injecting drugs, has been reported in the 
United Kingdom (Bundle et al., 2016).
I Infection risks among people who use drugs
Data on the extent of behavioural risks, such as the sharing 
of injecting equipment and unprotected sexual intercourse, 
and environmental factors, such as homelessness and 
imprisonment, can be important for understanding the 
potential for infections to spread, and for assessing the 
impact of interventions to reduce risk. The data available 
on these are limited at European level.
The usefulness of information from behavioural studies 
was shown in a presentation about the ANRS-Coquelicot 
sero-prevalence survey undertaken in the Paris region, 
France, in 2013 (Jauffret-Roustide, M., DRID meeting, 
2017; Jauffret-Roustide et al., 2017). This survey recruited 
689 people who had snorted or injected drugs and were 
using specialised services, including harm reduction 
facilities and addiction treatment centres; of these, 
150 were Russian speaking. The Russian speakers were 
migrants from countries of the former Soviet Union, 
especially from Georgia (57 %). The hepatitis C prevalence 
was twice as high among the Russian speakers as among 
the French speakers (88 % vs 44 %). The Russian speakers 
were more marginalised and had different behavioural and 
environmental risk profiles: they were more likely to use 
heroin and powder cocaine, and less likely to use crack 
cocaine and prescribed drugs; and they were more likely to 
have injected drugs in the past month (75 % vs 25 %), but 
those who had injected were less likely to report syringe 
sharing (11 % vs 26 %). Overall, the Russian speakers had 
a higher level of education, but most were unstably 
housed, with only 10 % living in stable accommodation 
FIGURE 8
Poster and leaflets produced in response to the Northern 
Ireland hepatitis C outbreak
Source: Jessop, L., DRID meeting, 2017.
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compared with half of the French speakers. 
Marginalisation, environmental factors and language 
barriers were identified as problems, which had negative 
impacts on access to services.
Regular bio-behavioural surveys of people who inject have 
been undertaken using respondent-driven sampling in 
Estonia. The most recent survey was undertaken was in 
Kohtla-Järve, north-east Estonia, during 2016 (Salekešin, 
M., DRID meeting, 2017). This was the third survey 
undertaken in this area; previous comparable surveys were 
in 2007 and 2012. Behavioural data collected in this 
survey programme indicate a decline in reported needle 
and syringe sharing during the preceding 28 days (from 
16 % to approx. 1 %) and an increase in the reported 
uptake of HIV testing (from 72 % to 97 %) over time.
I Hepatitis C and prisons
Prisons, and other closed settings, pose particular 
challenges to reducing the burden of infectious disease. In 
part, this is because they can be high-risk environments for 
contracting blood-borne infections, compounded by the 
fact that those entering prison may already have elevated 
levels of infection.
Data indicate that considerable opportunities exist in 
prisons for the scaling-up of interventions to prevent, 
diagnose and treat hepatitis C.
The general prison population in Europe (28 EU countries, 
Norway and Turkey) was around 125 per 100 000 
inhabitants, or about 770 000 people imprisoned in 
Europe on a given day (at 1 September 2015). There is 
marked variation in the level of imprisonment across the 
region (Figure 9).
Those who have been imprisoned report higher levels of 
lifetime drug use than the general population: in the 
15 countries reporting to the EMCDDA with data on 
lifetime use of any illicit drug among prisoners, this ranged 
from 21 % to 69 % (3). Those imprisoned also report high 
levels of lifetime injecting drug use. Injecting may also 
occur in the prison environment, as illustrated by a study 
conducted among current injectors, in 8 cities in Germany. 
In this study, of those who had ever been in prison, 
between 17.8 % in Leipzig and 39.3 % in Berlin reported 
injecting drugs while incarcerated (Robert Koch Institut, 
2016; Wenz, B. 2016).
(3) For one of the 15 countries (Croatia), cannabis prevalence was used. 
Prevalence of cannabis use is therefore a minimum estimate of any illicit 
drug use in 2015. See Drug use in prison in the 2017 Statistical bulletin.
The available data indicate that the prevalence of hepatitis 
B and C infection among those imprisoned can be high. 
Studies of prisoners in 11 European countries reported 
prevalence estimates between 0.3 % and 25 % for HBsAg 
and between 4.9 % and 86 % for anti-HCV (ECDC, 2016c). 
Limited recent data are available on prevalence rates 
among people who inject drugs, but the available studies 
have reported prevalences between 12 % and 97 % for 
anti-HCV (five countries, 2007 to 2013), between 0 % and 
0.5 % for HBsAg (two countries, 2009 to 2010) and 
between 0.2 % and 18 % for HIV (six countries, 2006 to 
2015) (EMCDDA, 2017c, INF 111, INF 108).
The provision of drug-related health interventions to 
reduce drug use related harm and infections in prisons is 
highly variable between countries. Screening for infections 
on entry to prison is a standard intervention, although 
often limited to detection of tuberculosis and HIV 
infections. Vaccination for hepatitis A and B and treatment 
of infections are measures recommended for the 
prevention and control of infections in community settings, 
but they are less frequently available in prisons; only one in 
three countries report their existence. Needle and syringe 
programmes are widely available in the community (see 
section ‘HCV prevention and treatment’ above; Figure 4), 
but are available in prisons in only Spain (17 prisons), 
Luxembourg (both prisons) and Germany (one prison). In 
Romanian prisons, needle and syringe programmes have 
been set up but no use is reported. While prison syringe 
provision is legally possible in the Portuguese prison 
system, there are no programmes currently operational.
FIGURE 9
General prison population rates in European countries 
(EU, Norway and Turkey) at 1 September 2015
>250200–250150–200<100 100–150
Prisoners per 100 000 population
Source: Aebi, 2016.
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Opioid substitution treatment is reported to be available in 
prisons in 26 EU countries (not in Lithuania or Slovakia) as 
well as in Norway and Turkey. However, in the countries 
that have introduced opioid substitution treatment in 
prison, this occurred later than in the community 
(Figure 10).
Although a range of interventions are available in prisons 
and are being used, infections continue to occur. An 
example is the recent outbreak HIV among prisoners in 
Lithuania during 2016 (Vaitkevičiūtė, I., DRID meeting, 
2017). This outbreak occurred in Alytus prison, the 
second-largest in Lithuania, and has been linked to illicit 
drug use. There were 38 new HIV diagnoses in the prison 
during that year, compared with an average of nine a year 
in the previous four years. There had previously been a 
large HIV outbreak in the same prison during 2002. In 
response, a range of measures were introduced in the 
prison under three broad themes: supply reduction, 
demand reduction and harm reduction. Lithuania is one of 
the few countries that does not offer opioid substitution 
treatment continuation upon imprisonment.
In response to the elevated risk of infection transmission in 
prisons, the EMCDDA is collaborating with the ECDC on 
producing evidence-based public health guidance to 
provide EU/EEA countries with options for prevention of 
communicable diseases in prison settings. As part of this 
work, systematic reviews of the evidence base regarding 
tuberculosis (ECDC, 2017c) and active case finding are 
being published; the guidance will ultimately cover a wide 
range of topic areas, also including vaccination and the 
prevention of blood-borne infections.
FIGURE 10
Implementation of opioid substitution treatment in community and prison: cumulative number of 28 EU Member States, 
Norway and Turkey with opioid substitution treatment in community and prison settings over time
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I Drug consumption rooms
Drug consumption rooms are professionally supervised 
healthcare facilities where people who use drugs can do 
so in a safe, hygienic environment (EMCDDA, 2017d). 
These facilities are usually publicly funded, and targeted to 
address the needs of a defined group of highly 
marginalised people who use drugs. These often include 
homeless people who use drugs in specific locations 
associated with drug use, sometimes referred to as ‘open 
drug scenes’, or in other public spaces, sometimes 
including temporary housing or hostels. Drug consumption 
rooms are usually established to address situations where 
drug use in public places persists, despite a range of drug 
treatment and harm reduction interventions being 
available. The facilities are established to mitigate the 
effects of high-risk drug use environments on individual 
and public health and to respond to safety concerns 
among the local community.
Drug consumption rooms have been established in 
Europe, Australia (in Sydney) and Canada (two in 
Vancouver, with more planned elsewhere). As of June 2017 
there were 90 official drug consumption rooms in Europe, 
of which 76 are in six EU countries (31 in the Netherlands, 
24 in Germany, 13 in Spain, five in Denmark, two in France 
and one in Luxembourg), two in Norway and 12 in 
Switzerland (Figure 11). France opened its first two drug 
consumption facilities in 2016 as part of a pilot study, after 
many years of planning (Avril, E. and Marie Jauffret-
Roustide, M., DRID meeting, 2017).
The emergence of an open drug scene in the north-east of 
Paris, around 2007, caused concern, as people using drugs 
were often injecting morphine sulphate or smoking crack 
cocaine in car parks, building entrances or public toilets or on 
the streets. In response, a proposal for a drug consumption 
room, produced by a collective action involving a range of 
stakeholders, was initially submitted to the Ministry of Health 
in 2009. In January 2016, with the adoption of the 
Modernisation of Public Health Law, it became possible to set 
up a drug consumption room in France. This followed 
extensive lobbying and community action. Article 43 of the 
new law allows drug consumption rooms as an experiment 
for six years. The first room opened in Paris in October 2016 
(Figure 12). At the time of writing, the room had been used by 
669 people, who had made 31 383 visits, with 21 897 
injections. On average, there are about 200 visits per day: 
43 % of those attending inject morphine sulphate; and 43 % 
use crack, a third of whom inject it and the rest smoke it. A 
second drug consumption room has since opened in 
Strasbourg. The project will be evaluated using a cohort 
study — the Cosinus Cohort — in four cities, two with and 
two without drug consumption rooms. The study will look at 
the impact of drug consumption rooms on HIV and HCV risk 
practices and other drug use related harms.
FIGURE 11
Location and number of drug consumption facilities throughout Europe, 2017
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Three European countries are currently considering the 
possibility of establishing their first drug consumption 
rooms: Belgium, Ireland and the United Kingdom.
I  Drug use and sexual risks among men who have sex with men
Studies suggest illicit drug use can be more common 
among some minority groups. Although the reasons for 
these differences remain unclear, they are likely to be 
complex. In recent years, there has been concern about 
drug use among lesbian, gay, bisexual and transgender 
(LGBT) communities. The emergence of a particular 
pattern of sexualised drug use — often referred to as 
`chemsex’ or `Party and Play’ (PnP) — among some 
subgroups of men who have sex with men is of concern. 
Sexualised drug use — that is, drugs being used to 
enhance or facilitate sex — is not a new phenomenon 
among LGBT communities or other population groups.
Recent findings on the extent of drug use among men who 
have sex with men were presented. They were derived 
from the SIALON II study, which was undertaken in 
13 cities across Europe during 2013-14 (Rosińska, M., 
DRID meeting, 2017; www.sialon.eu/en/). The survey 
recruited approximately 400 men who have sex with men 
from the community in each city. The participants 
completed a behavioural questionnaire and provided a 
biological sample. The study, unsurprisingly, found that the 
use of drugs was common. The median level of alcohol use 
across the cities was 42 % (range of 25-67 %), poppers 
13 % (3.8-36 %) and cannabis 5.9 % (1.9-12 %). The use of 
one or more of the drugs that are commonly used in 
nightclubs and other ‘party’ settings (i.e. cocaine, 
amphetamine, ketamine, gamma-hydroxybutyric acid 
(GHB), mephedrone and 3,4-methylenedioxy-
methamphetamine (MDMA)) was reported by 6.8 % 
(2.0-15 %; Figure 13). Initial findings from an ongoing 
analysis of the survey data suggest that those who report 
using one or more of these ‘party drugs’ may be less likely 
to use condoms with non-regular partners. These findings 
corroborate previous ones indicating that levels and 
patterns of drug use among men who have sex with men 
vary across Europe and may increase infection risk.
FIGURE 12
Facilities inside the new drug consumption room in Paris
Source: Avril, E., DRID meeting, 2017.
FIGURE 13
‘Party drug’ use prior to or during sex among men who 
have sex with men in 13 cities: SIALON II study, 2013-14
0
5
10
15
20
25
30
35
40
45
50
B
ra
tis
la
va
(S
lo
va
ki
a)
H
am
b
u
rg
(G
er
m
an
y)
V
iln
iu
s
(L
it
h
u
an
ia
)
S
to
ck
h
o
lm
(S
w
ed
en
)
W
ar
sa
w
(P
ol
an
d
)
V
er
o
n
a
(I
ta
ly
)
Lj
u
b
lja
n
a
(S
lo
ve
n
ia
)
S
o
­a
(B
u
lg
ar
ia
)
Li
sb
on
(P
or
tu
ga
l)
B
ar
ce
lo
n
a
(S
p
ai
n
)
B
u
ch
ar
es
t
(R
om
an
ia
)
B
ri
g
h
to
n
 
(U
n
it
ed
 K
in
gd
om
)
B
ru
ss
el
s
(B
el
gi
u
m
)
Percent
NB: ‘Party drug’ signifies any of the following: cocaine, amphetamine, 
ketamine, GHB, mephedrone and MDMA. 
Source: Mirandola et al., 2016, Chapter 5.12.
18
Drug-related infectious diseases in Europe
There is a large ongoing multi-country outbreak of hepatitis 
A in Europe; 1 500 confirmed cases and 2 660 probable or 
suspected cases had been reported in the European Union 
to June 2017. These cases are predominantly among men 
who have sex with men (ECDC, 2017a). The response to 
the outbreak in Berlin, Germany, was presented 
(Zimmermann, R., DRID meeting, 2017). There had been 
119 hepatitis A cases in Berlin between 16 November 
2016 and the date of the meeting. Of these cases, 71 are 
known to be among men who have sex with men. As part 
of the outbreak investigation, 44 (including 42 men who 
have sex with men) were interviewed. The use of gay 
dating apps and gay venues was common. Overall, 78 % of 
the men who have sex with men reported alcohol or drug 
use at sexual contact at least once, with a fifth reporting 
this at every contact. Of those who reported drug or 
alcohol use every time or most times, 43 % used both 
drugs and alcohol, 7 % only drugs and 50 % only alcohol. In 
response, a range of measures have been taken, including 
improving access to the hepatitis A vaccination, and 
information campaigns in German and English on dating 
apps and in venues (Figure 14).
In Portugal (Duran, D., DRID meeting, 2017), there have 
been 115 hepatitis A cases reported in 2017 (up to 29 
March), 97 % among young men. Molecular analysis of 
samples from 55 indicate that 53 had strains associated 
with cases among men who have sex with men in other 
European countries. Drug use data are not collected with 
case reports, but available information on drug use among 
men who have sex with men in Portugal suggests that 
chemsex is rare.
These data suggest that sexualised drug use may be one 
of several factors contributing to the current hepatitis A 
outbreak among men who have sex with men in some of 
the countries affected. Responding to sexualised drug use 
and reducing the associated harms, among men who have 
sex with men or other groups, will require a 
multidisciplinary approach, in particular collaboration 
between sexual health, experts on drug use and 
community groups.
I In brief
European Parliament resolution on the European 
Union’s response to HIV/AIDS, tuberculosis and 
viral hepatitis
In June 2017, the plenary of the European Parliament in 
Strasbourg adopted a key resolution on the European 
Union’s response to HIV/AIDS, tuberculosis and viral 
hepatitis. This calls on the European Commission and EU 
Member States to develop a comprehensive policy 
framework for addressing these three diseases jointly. The 
resolution acknowledges the role of injecting drug use as a 
major driver of the hepatitis C epidemic in the WHO 
European Region, and the importance of providing 
comprehensive harm reduction services for people who 
inject drugs.
FIGURE 14
Information materials about hepatitis A targeted at men 
who have sex with men in Berlin
Source: State Office for Health and Social Affairs Berlin, Germany, DRID 
meeting, 2017.
Chemsex: definition and possible harms
‘Chemsex’ is a particular manifestation of sexualised 
drug use that involves the use of specific drugs as an 
integral part of, often planned, sexual activity 
involving multiple partners. The drugs are used to 
enhance sexual confidence, and to disinhibit and 
prolong sexual activity and arousal, with crystal meth, 
GHB/gamma-butyrolactone (GBL), ketamine and 
mephedrone commonly being used (Bourne et al., 
2014). The use of crystal meth can easily become a 
problem, the use of GHB/GBL and ketamine can be 
particularly dangerous, and drugs are sometimes 
injected. Condoms are often not used. Thus this 
phenomenon can lead to significant harms including 
the transmission of HIV, HCV and sexually 
transmitted infections. Although the extent of 
chemsex remains unclear, its emergence is a concern 
and has led to closer examination of drug use risks 
more generally among men who have sex with men.
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Lisbon Addictions 2017
The second European conference on addictive behaviours 
and dependencies will be held in Lisbon from 24 to 26 
October. The event is organised jointly by the Portuguese 
General-Directorate for Intervention on Addictive 
Behaviours and Dependencies (SICAD), the journal 
Addiction, the EMCDDA and the International Society of 
Addiction Journal Editors (ISAJE) (http://www.
lisbonaddictions.eu/).
Updates on European joint actions and projects
Three major European projects, and a project from Lisbon, 
had the opportunity to share their work in a ‘world café’ 
format during the 2017 DRID/ECDC hepatitis network 
meeting.
 § HA-REACT (Joint Action on HIV and Co-infection 
Prevention and Harm Reduction): The work of HA-
REACT is centred on improving the capacity to respond 
to HIV and co-infection risks, and in particular the 
provision of harm reduction with a specific focus on 
people who inject drugs in the European Union. HA-
REACT works together with 22 partners from 18 
countries. While the focus countries are Hungary, Latvia 
and Lithuania, activities take place across the European 
Union (www.hareact.eu/en/about-ha-react).
 § HepCare Europe: This EU-funded study aims to improve 
access to HCV testing and treatment among key risk 
groups, including drug users and homeless people, 
through outreach to the community and integration of 
primary and secondary care services (www.ucd.ie/
medicine/hepcare/). It works in four sites (Dublin, 
London, Seville and Bucharest). After one year in Dublin, 
for example, 547 people using the homeless service 
had been tested for HCV using point of care testing, and 
outreach fibro-scanning had successfully been 
introduced into selected treatment centres.
 § E-DETECT TB: This is an EU-funded consortium that 
aims to improve the early detection and case 
management of tuberculosis in Europe 
(https://e-detecttb.eu/). Its programme of work prioritises 
people who use drugs, homeless people, prisoners, 
migrants and those with multi-drug-resistant tuberculosis. 
Working in partnership with government services, NGOs 
and affected communities, this project will screen people 
at risk in Romania and Bulgaria using a mobile X-ray unit 
equipped with computer-aided diagnostics and on-the-
spot molecular tuberculosis testing.
 § In-Mouraria: Grupo de Ativistas em Tratamentos (GAT) 
presented this local community-based project. Based in 
Lisbon, Portugal, it focuses on safer drug use; access to 
health and social services for people who use drugs or 
alcohol, including access to treatment; increased 
integration of people who use drugs; and tackling stigma 
and discrimination (http://www.gatportugal.org/).
I References
I  Aebi, M. F., Tiago, M. M. and Burkhardt, C. (2016), SPACE I 
– Council of Europe Annual Penal Statistics: Prison populations. 
Survey 2015, Council of Europe, Strasbourg (http://wp.unil.ch/
space/files/2017/04/SPACE_I_2015_FinalReport_161215_
REV170425.pdf).
I  Bourne, A., Reid, D., Hickson, F., Torres Rueda, S. and 
Weatherburn, P. (2014), ‘The Chemsex study: drug use in sexual 
settings among gay and bisexual men in Lambeth, Southwark 
and Lewisham’, Sigma Research, London School of Hygiene and 
Tropical Medicine (http://www.sigmaresearch.org.uk/chemsex).
I  Bundle, N., Bubba, L., Coelho, J., et al. (2017), ‘Ongoing outbreak of 
invasive and non-invasive disease due to group A Streptococcus 
(GAS) type emm66 among homeless and people who inject drugs 
in England and Wales, January to December 2016’, 
Eurosurveillance 22(3):pp1-6 (http://www.eurosurveillance.org/
images/dynamic/EE/V22N03/art22693.pdf).
I  Duffell, E. F., Hedrich, D., Mardh, O. and Mozalevskis, A. (2017), 
‘Towards elimination of hepatitis B and C in European Union and 
European Economic Area countries: monitoring the World Health 
Organization’s global health sector strategy core indicators and 
scaling up key interventions’, Eurosurveillance 22(9):pp 1-5 
(http://www.eurosurveillance.org/images/dynamic/EE/
V22N09/art22728.pdf).
I  EASL (2016), Recommendations on treatment of hepatitis C 
2016 (http://www.easl.eu/research/our-contributions/
clinical-practice-guidelines/detail/easl-recommendations-on-
treatment-of-hepatitis-c-2016).
I  ECDC (European Centre for Disease Prevention and Control) 
and EMCDDA (European Monitoring Centre for drugs and drug 
addiction) (2015), Wound botulism in people who inject heroin in 
Norway and the United Kingdom, ECDC/EMCDDA, Lisbon 
(http://www.emcdda.europa.eu/publications/joint-publications/
wound-botulism-norway-uk-2015_en).
I  ECDC (European Centre for Disease Prevention and Control) 
and WHO (World Health Organization) Regional Office for 
Europe (2016), HIV/AIDS surveillance in Europe 2015, ECDC, 
Stockholm (https://ecdc.europa.eu/en/publications-data/
hivaids-surveillance-europe-2015).
I  ECDC (European Centre for Disease Prevention and Control) 
(2016a), Vaccine schedule (http://vaccine-schedule.ecdc.
europa.eu/Pages/Scheduler.aspx).
I  ECDC (European Centre for Disease Prevention and Control) 
(2016b), Summary of public health threats, CDTR week 30/2016 
(https://ecdc.europa.eu/en/news-events/summary-public-
health-threats-cdtr-week-302016).
I  ECDC (European Centre for Disease Prevention and Control) 
(2016c), Systematic review on hepatitis B and C prevalence in 
the EU/EEA (https://ecdc.europa.eu/en/publications-data/
systematic-review-hepatitis-b-and-c-prevalence-eueea).
20
Drug-related infectious diseases in Europe
I  ECDC (European Centre for Disease Prevention and Control) 
(2017a), Rapid risk assessment: Hepatitis A outbreak in the EU/
EEA mostly affecting men who have sex with men, 3rd update 
(https://ecdc.europa.eu/en/publications-data/rapid-risk-
assessment-hepatitis-outbreak-eueea-mostly-affecting-men-
who-have-sex).
I  ECDC (European Centre for Disease Prevention and Control) 
(2017b), Hepatitis B: annual epidemiological report for 2015 
(https://ecdc.europa.eu/en/publications-data/hepatitis-b-
annual-epidemiological-report-2015).
I  ECDC (European Centre for Disease Prevention and Control) 
(2017c), Systematic review on the diagnosis, treatment, care and 
prevention of tuberculosis in prison settings (https://ecdc.
europa.eu/en/publications-data/systematic-review-diagnosis-
treatment-care-and-prevention-tuberculosis-prison).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (2016a), Drug-related infectious diseases in Europe: 
update from the EMCDDA expert network, Publications Office of 
the European Union, Luxembourg (http://www.emcdda.europa.
eu/publications/rapid-communications/2016/drug-related-
infectious-diseases-in-europe).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (2016b), Hepatitis C among drug users in Europe. 
Epidemiology, treatment and prevention, EMCDDA Insights 
Series No 23, Publications Office of the European Union, 
Luxembourg (http://http://www.emcdda.europa.eu/
publications/insights/hepatitis-c-among-drug-users-in-europe).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (2017a), Drugnet Europe 99 (http://www.emcdda.
europa.eu/publications/drugnet/99).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (2017b), European drug report 2017: trends and 
developments, Publications Office of the European Union, 
Luxembourg (http://www.emcdda.europa.eu/publications/edr/
trends-developments/2017).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (2017c), Statistical bulletin 2017 (http://www.
emcdda.europa.eu/data/stats2017/drid).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (2017d), Drug consumption rooms: an overview of 
provision and evidence, Perspectives on drugs (http://www.
emcdda.europa.eu/topics/pods/drug-consumption-rooms).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (n.d.), Best practice portal (http://www.emcdda.
europa.eu/best-practice/answer-sheets/treatment-opioid-
users_en).
I  EMCDDA and Europol (2017), EMCDDA-Europol 2016 Annual 
Report on the implementation of the Council Decision 2005/387/
JHA (http://www.emcdda.europa.eu/system/files/
publications/4724/TDAN17001ENN_PDFWEB.pdf).
I  Jauffret-Roustide, M., Serebroskhaya, D., Chollet, A., et al. (2017), 
‘Comparaison des profils, pratiques et situation vis-à-vis de 
l’hépatite C des usagers de drogues russophones et 
francophones à Paris, ANRS-Coquelicot Study, 2011-2013’, 
Bulletin Epidémiologique Hebdomadaire 14-15, pp. 285-290 
(http://invs.santepubliquefrance.fr/beh/2017/14-15/2017_14-
15_5.html).
I  Léon, L., Kasereka, S., Barin, F., et al. (2016), ‘Age and time-
dependent prevalence and incidence of hepatitis C virus 
infection among drug users in France, 2004-2011: model-based 
estimation from two national cross-sectional serosurveys’, 
Epidemiology & Infection 22, pp. 1-13.
I  Mirandola, M., Gios, L., Sherriff, N., Toskin, I., Urlich, M., Schink, S., 
Suligoi, B., Folch, C. and Rosinska, M. (eds.) (2016), The Sialon II 
project: report on a bio-behavioural survey among MSM in 13 
European cities, Cierre Grafica, Verona, Italy.
I  Page-Shafer, K., Pappalardo, B. L., Tobler, L. H. et al. (2008), 
‘Testing strategy to identify cases of acute hepatitis C virus 
(HCV) infection and to project HCV incidence rates’, Journal of 
Clinical Microbiology 46, pp. 499-506.
I  Patel, E. U., Cox, A. L., Mehta, S. H., et al. (2016), ‘Use of hepatitis 
C virus (HCV) immunoglobulin G antibody avidity as a biomarker 
to estimate the population-level incidence of HCV infection’, 
Journal of Infectious Diseases 214, pp. 344-352.
I  Platt, L., Minozzi, S., Reed, J., et al. (2017), Needle syringe 
programmes and opioid substitution therapy for preventing HCV 
transmission among people who inject drugs: findings from a 
Cochrane Review and meta-analysis, Addiction, Advance online 
publication doi: 10.1111/add.14012.
I  Robert Koch Institut (2016), Abschlussbericht der Studie 
„Drogen und chronischen Infektionskrankheiten in Deutschland“ 
(DRUCK-Studie). Berlin, Germany. DOI: 10.17886/
rkipubl-2016-007.2
I  Stanaway, J., Flaxman, A., Naghavi, M., et al. (2016), The global 
burden of viral hepatitis from 1990 to 2013: findings from the 
Global Burden of Disease Study 2013. The Lancet, 388, pp. 
1081-1088 (http://www.sciencedirect.com/science/article/pii/
S0140673616305797?via%3Dihub#).
I  WHO (World Health Organization) (2016a), Global health sector 
strategies on viral hepatitis, 2016-2021 (www.who.int/hepatitis/
strategy2016-2021/ghss-hep/en/).
I  WHO (World Health Organization) (2016b), Guidelines for the 
screening, care and treatment of persons with chronic hepatitis 
C infection (www.who.int/hepatitis/publications/hepatitis-c-
guidelines-2016/en/).
I  WHO European Office (2016), Action plan for the health sector 
response to viral hepatitis in the WHO European Region (www.
euro.who.int/en/health-topics/communicable-diseases/
hepatitis/publications/2016/action-plan-for-the-health-sector-
response-to-viral-hepatitis-in-the-who-european-region.-
draft-2016).
I  Wenz, B., Nielsen, S., Gassowski, M., et al. (2016), ‘High variability 
of HIV and HCV seroprevalence and risk behaviours among 
people who inject drugs: results from a cross-sectional study 
using respondent-driven sampling in eight German cities 
(2011–14)’, BMC Public Health 16(1): 1-14 (https://
bmcpublichealth.biomedcentral.com/articles/10.1186/
s12889-016-3545-4).
21
Update from the EMCDDA expert network I October 2017
I Resources and latest data available
 § European Commission (2017), EU action plan on drugs 2017-20 (2017/C 215/02) (http://eur-lex.europa.eu/
legal-content/EN/TXT/PDF/?uri=CELEX:52017XG0705(01)&from=EN).
 § EMCDDA (n.d.), Drug-related infectious diseases key epidemiological indicator (www.emcdda.europa.eu/activities/
drid).
 § EMCDDA (n.d.), Best practice portal (http://www.emcdda.europa.eu/best-practice).
 § Data on epidemiology and responses are available from EMCDDA (2017), Statistical Bulletin 2017 (http://www.
emcdda.europa.eu/data/stats2017).
 § ECDC (2017), Hepatitis C: annual epidemiological report for 2015 (https://ecdc.europa.eu/en/hepatitis-c-annual-
epidemiological-report-for-2015).
 § ECDC (2017), Hepatitis B and C testing activities, needs, and priorities in the EU/EEA (https://ecdc.europa.eu/sites/
portal/files/documents/HepatitisBC-testing-in-EU-May2017.pdf).
 § Cook, C. (2017), Harm reduction investment in the European Union: current spending, challenges and successes, 
Harm Reduction International (https://www.hri.global/contents/1782).
 § WHO (2016), Guidelines on hepatitis B and C testing, Policy brief, WHO/HIV/2016.23 (http://www.who.int/
hepatitis/publications/hepatitis-testing-recommendation-policy/en/).
 § WHO (2017), Global hepatitis report (http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/).
I Acknowledgements
The EMCDDA acknowledges the input of the national 
experts on drug-related infectious diseases, the invited 
experts and the Reitox national focal points. Linda 
Montanari and Luis Royuela assisted in the production of 
this report. Erika Duffell from ECDC, as well as Julian 
Vicente and Peter Fay provided helpful comments. Our 
thanks go as well to the speakers named in this report for 
sharing their presentations and commenting on the draft. 
The list of participants and speakers at the expert meeting 
is available from the meeting web page: http://www.
emcdda.europa.eu/meetings/2017/drid.
22
Drug-related infectious diseases in Europe
I Appendixes
I Appendix 1
Estimates of the prevalence of injecting drug use (rate per 1 000 population aged 15-64), last study available
Country Year
Injecting drug use prevalence 
(per 1 000 population aged 15-64)
Estimated number of users
Central Lower Upper Central estimate Lower bound Upper bound
Belgium 2015 3.28 2.32 4.61 23 828 16 841 33 517
Czech Republic 2015 6.25 6.12 6.38 43 900 43 000 44 800
Estonia 2009 5.89 4.29 10.8 5 362 3 906 9 837
Greece 2015 0.77 0.6 1.02 5 397 4 225 7 129
Spain 2014 0.24 0.18 0.31 7 578 5 634 9 522
France 2014 2.59 2.1 3.2 105 000 85 300 130 000
Croatia 2015 2.21 1.79 2.87 6 344 5 147 8 255
Cyprus 2015 0.42 0.3 0.67 198 141 316
Latvia 2012 9.22 7.34 11.68 12 573 10 003 15 914
Luxembourg 2009 5.68 4.5 6.85 1 907 1 524 2 301
Hungary 2015 0.98 6 707
Portugal 2012 2.2 1.94 2.46 14 426 12 732 16 101
Finland 2012 4.6 4.1 6.7 15 611 13 770 22 665
Sweden 2008-11 1.31 8 021
United Kingdom 2004-11 3 2.87 3.22 122 894 117 370 131 869
Norway 2014 2.47 2.2 2.98 8 393 7 459 10 141
NB: The estimates are based on several sources and statistical methods (e.g. capture-recapture, mortality multiplier) and not only on treatment data. They may 
underestimate the prevalence of injection, as some substances may not appear in the sources used (e.g. these estimates will not include image and perfor-
mance enhancing drugs). Caution is required when comparing countries. More information is available from http://www.emcdda.europa.eu/activities/hrdu. 
Source: EMCDDA, 2017b.
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I Appendix 2
Hepatitis C situation among people who inject drugs in 28 European countries, Norway and Turkey: 
prevalence and prevention
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NR, Not reported.
Source: Reports of the national focal points through EMCDDA standard tables ST9 (DRID), ST10 (syringe availability) and ST24 (availability and access to 
treatment/number of clients in opioid substitution treatment); EMCDDA, 2017b; Updates provided by the experts: Prevalence survey among clients of a drug 
consumption room in Luxembourg, 2016-17 (Devaux, C., DRID meeting, 2017).
25
Update from the EMCDDA expert network I October 2017
Getting in touch with the EU
In person
All over the European Union there are hundreds of Europe Direct Information Centres. You can 
find the address of the centre nearest you at: http://europa.eu/contact
On the phone or by e-mail
Europe Direct is a service that answers your questions about the European Union. You can 
contact this service 
– by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls), 
– at the following standard number: +32 22999696 or 
– by electronic mail via: http://europa.eu/contact
Finding information about the EU
Online
Information about the European Union in all the official languages of the EU is available on the 
Europa website at: http://europa.eu  
EU Publications
You can download or order free and priced EU publications from EU Bookshop at: 
http://publications.europa.eu/eubookshop. Multiple copies of free publications may be 
obtained by contacting Europe Direct or your local information centre (see http://europa.eu/contact)
EU law and related documents
For access to legal information from the EU, including all EU law since 1951 in all the official 
language versions, go to EUR-Lex at: http://eur-lex.europa.eu
Open data from the EU
The EU Open Data Portal (http://data.europa.eu/euodp) provides access to datasets from the 
EU. Data can be downloaded and reused for free, both for commercial and non-commercial purposes.
About this publication
Rapid communications bring you the latest findings 
and discussions in key areas in the drugs field. This 
report provides an update on infectious diseases 
related to injecting drug use in Europe. It covers both 
the EMCDDA Drug-related infectious diseases 
indicator, which collects data on the situation, and the 
responses in the area. The report is based on the 
indicator’s annual expert meeting, held in Lisbon in 
June 2017, which brought together national experts 
from the 28 EU Member States, Norway, Turkey, 
European neighourhood countries and partner 
organisations.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
